Objectives: We describe the clinical characteristics, prevalence and control of coronary artery disease (CAD) risk factors of the Indian cohort enrolled in the CLARIFY registry and compare them with data from rest of the world (ROW). Methods: CLARIFY is an international, prospective, observational, longitudinal cohort study in stable CAD outpatients. The baseline data of Indian cohort (n = 709) were compared to ROW (n = 31994). Results: The CLARIFY India patients were significantly younger than the ROW (59.6 AE 10.9 vs 64.3 AE 10.4). Indian patients were more likely than those in ROW to have diabetes (42.9% vs 28.8%) and angina (27.8% vs 21.9%). Mean heart rate was significantly greater in Indians measured by either palpatory method (76.1 AE10.4 vs 68.0 AE 10.5) or ECG (74.9 AE 12.9 vs 67.0 AE 11.3). The use of aspirin (85.6% vs 87.8%), b-blockers (69.4% vs 75.4%), and lipid-lowering agents (90% vs 92.4%) was lower in India. A significantly greater proportion of patients in India exhibited low HDL cholesterol (41.6% vs 31.2%), and heart rate !70 bpm (82.2% vs 48.5%). The risk factors control was poor in India with heart rate goal of 60 bpm achieved in 2.5%; HbA1c <7% in 9.9%; and HbA1c <6.5% in 4.6% patients. Conclusion: The CLARIFY registry demonstrates a high prevalence and poor control of cardiovascular risk factors in Indian patients. Systematic efforts to improve risk factor control are required.
Introduction
Coronary artery disease (CAD) is the leading cause of cardiovascular morbidity and mortality worldwide, contributing to over 7 million deaths annually. 1 Regardless of a recent decline in CAD mortality in the developed countries, 2 
the burden of CAD in
India is rising remarkably. The national commission on macroeconomics and health estimated about 359 lakh CAD cases in 2005 that has been projected to rise up to 615 lakhs in 2015, 3 with the corresponding loss of the national income of approximately 237 billion USD in India. 4 These estimates draw special attention to the urgent need of aggressive strategies for the prevention and control of CAD in India.
A line of evidence indicates that the Indians are more susceptible to CAD and manifest higher mortality rate than their western counterparts. [5] [6] [7] [8] The fact may be attributed to diverse risk factors distribution and control across various geographical locations in India. 9 Therefore, one of the crucial strategies in the primary prevention of CAD could be achieving the risk factors control, which has been emphasised even in recent clinical practice guidelines. 10, 11 Although, there are enormous advances in the secondary prevention of CAD as witnessed by numerous clinical trials of antiplatelet therapy, statins, and angiotensin-converting enzyme inhibitors, the data on contemporary clinical practice management of CAD and its impact on clinical outcomes are scarce in India. Moreover, the available epidemiological data are not derived from well-designed high-quality studies, and majorly included patients with acute coronary syndrome with limited information on outpatients with stable CAD. 12, 13 Bridging this gap, the Prospective Observational Longitudinal Registry of patients with stable coronary artery disease (CLARIFY) registry was carried out across 45 geographical regions of the world with the objectives to gain information on their demographic characteristics, clinical presentation, and management of CAD. The registry also intends to study clinical outcomes of these patients and identify the longterm prognostic factors determining the clinical outcomes. This communication describes the clinical characteristics, prevalence and control of risk factors for CAD in India and compares them with the rest of the world (ROW) by analysing data from global CLARIFY registry.
Methods

Study design
CLARIFY is an international, prospective, observational, longitudinal cohort study in stable CAD outpatients with 5 years of follow-up. Detailed methods have been published previously.
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Patient selection
Stable CAD patients with at least one of the following: coronary stenosis >50% on coronary angiography; documented myocardial infarction (MI, >3months ago); chest pain with myocardial ischemia proven using stress electrocardiogram stress echocardiography, or myocardial imaging; history of coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI; performed >3 months ago), were enrolled in the registry. Patients with planned revascularisation, patients hospitalised for cardiovascular disease (CVD) (included revascularisation) 3 months prior to enrolment, patients with conditions anticipated to impede 5-year follow-up (e.g. serious non-cardiovascular disease, conditions limiting life expectancy, limited cooperation or legal capacity, or severe CVD [advanced heart failure, severe valve disease, history of valve repair/replacement, etc]), were excluded from the study.
Data collection and selection of patients for India sub-study
The information collected included demographic characteristics; risk factors and lifestyle; medical history included present symptoms; physical examination; cardiac evaluation included measuring the heart rate (HR) by pulse palpation and the resting electrocardiogram within the previous 6 months. Blood pressure both systolic and diastolic was recorded. All patients had an ECG taken and a record of rhythm documented. Blood tests recorded included haemoglobin, fasting blood glucose, HbA 1 c, serum triglycerides and cholesterol, and serum creatinine, if available.
A note was made of current medications taken regularly by the patient for !7 days before entry in the registry.
In the current paper, only the patients recruited from India (709) were compared with rest of the world.
Ethics
The registry was conducted in line with the principles outlined in the Declaration of Helsinki and was approved by the National Research Ethics Service, Isle of Wight, Portsmouth, and Southeast Hampshire Research Ethics Committee, UK. Approval was also obtained in all participating centres in accordance with local regulations. All patients provided written informed consent. The ISRCTN registration number of CLARIFY is ISRCTN43070564.
Statistical analysis
Data are summarised as mean with standard deviation or median with interquartile range. Categorical data are presented as counts and percentages. Data were analysed by x2 tests or Fisher's exact test for categorical and t-test or Mann-Whitney U test for continuous variables using 2-sided tests at a significance level of 5% using Statistical Analysis Software (version 9.2).
Results
The global CLARIFY registry included a total of 32703 analysable patients, of these, Indian cohort comprised of 709 (2.2%) stable CAD patients.
Patient characteristics
A majority of baseline characteristics and lifestyle practices of CLARIFY India cohort were similar to the ROW population ( Table 1) . The CLARIFY India patients were significantly younger than the ROW (59.6 AE 10.9 vs 64.3 AE 10.4). Indian patients were more likely than those in the ROW to have diabetes (42.9% vs 28.8%), but less likely to have a family history of premature CAD (21.3% vs 28.7%), dyslipidaemia (63% vs 75.2%), peripheral arterial disease (4.8% vs 10%), aortic abdominal aneurysm (0.1% vs 1.6%), and carotid disease (1.8% vs 7.7%) ( Table 2) . Indian participants had less frequent history of MI (55.3% vs 60%), PCI (42.5% vs 59%) and CABG (20.7% vs 23.6%) than the ROW patients. The mean HR (bpm) of CLARIFY Table 1 Baseline demographic characteristics and lifestyle of patients. Indian cohort was significantly higher when compared to the ROW; measured by both palpation (76.1 AE10.4 vs 68.0 AE 10.5) and ECG (74.9 AE 12.9 vs 67.0 AE 11.3). Angina was significantly more prevalent in India (27.8% vs 21.9%).
Medical therapies
The use of selected chronic cardiovascular medications at enrolment is presented in Table 3 . Overall, a major proportion of the India and the ROW cohorts were taking guideline-recommended therapy. The use of anti-platelets was high with aspirin being the most commonly used (85.6% vs 87.8%) in India vs ROW.
Thienopyridine (54.9% vs 26.6%) and dual anti-platelets (53.3% vs 27.4%) were prescribed to significantly higher proportion of patients in India than the ROW. The use of b-blockers (69.4% vs 75.4%) and ivabradine (5.4% vs 9.9%) was significantly lower in India compared to the ROW. Though a total of 90% and 92.4% patients in India and the ROW, respectively, used lipid lowering agents, there was less frequent use of statin in India (77.9% vs 90%).
Risk factors and their control
In general, the prevalence of cardiovascular risk factors was very high in CLARIFY India cohort compared to the ROW (Figs. 1 and 2). The Indian cohort was less likely to be overweight (76.1% vs 89.2%) and obese (27.2% vs 48.4%) than the ROW. A significantly greater proportion of patients in India displayed dyslipidaemia, notably raised LDL cholesterol (70.3% vs 79.3%) and low HDL cholesterol (41.6% vs 31.2%). The remarkably high proportion of Indian patients exhibited elevated HR (!70 bpm) than the ROW (82.2% vs 48.5, p < 0.0001), and only 2.5% in India vs 22.9% in the ROW achieved the HR goal of 60 bpm when presented with symptoms of angina. About 9.9% and 4.6% patients achieved HbA 1 c <7% and HbA 1 c <6.5%, respectively, in India.
Discussion
The CLARIFY registry is an international, prospective, observational longitudinal registry focused on outpatients with stable CAD.
Similar to the previous epidemiological studies, 17, 18 the prevalence of cardiovascular risk factors was higher in CLARIFY India cohort. CLARIFY India results witnessed lower prevalence of overweight and obesity than the ROW. These findings are consistent with the WHO estimates that show a relatively low rate of overweight and obesity in India. 19 However, there is a strong evidence that the metabolic consequences of obesity, dyslipidaemia (particularly hypertriglyceridemia, low HDL and increased numbers of small dense LDL particles) and dysglycaemia (insulin resistance and type 2 diabetes), are apparent at lower absolute levels of total body fat in South Asians than in whites. In agreement with these facts, the proportion of patients with raised LDL-C, reduced HDL-C, and diabetes (with poor glycaemic control) were greater in CLARIFY India cohort. Moreover, one of the remarkable characteristics was younger age of the Indian cohort than the ROW. The results are in agreement with the results of the INTERHEART study, an international case-control study carried out in 52 countries, including India, involving 15152 cases of acute MI. 20 The study has shown a high prevalence of cardiovascular risk factors even among controls who were less than sixty years of age. One of the crucial strategies for prevention of CAD universally recommended by evidence-based guidelines includes comprehensive management of modifiable risk factors, which includes weekly physical activity, weight management, smoking/tobacco cessation, [ Fig. 2 . Control of risk factors in India and the rest of the world (all p < 0.05). BP <140/90 mm Hg in patients with hypertension; LDL cholesterol <0.7 g/L in patients with dyslipidaemia; HbA 1 c <7% in patients with diabetes; HbA 1 c <6.5% in patients with diabetes; Heart rate 60 bpm in patients with symptoms of angina BP, blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; HR, heart rate; ROW, rest of the world. and dietary modification. 21 The findings from this sub-set analysis ( 24 Moreover, underused treatments, lack of awareness among patients and the physician, and non-adherence to medications are some of the factors responsible for poor management, despite the sheer scale of CVD prevalence in India. [25] [26] [27] All these factors mandate systematic interventions to improve the long-term use of basic, inexpensive, and effective drugs. Determining the long-term prognostic value of HR remains the imperative objective of the CLARIFY. The data on clinical outcomes after 5 year follow-up of these Indian CAD patients is intended to be published separately. Taking into account the increased cardiovascular risk with elevated HR, 28 several recent clinical practice guidelines have emphasised HR reduction as a substantial cardiovascular risk management strategy. 11 In the similar context, the mean HR and proportion of patients having HR !70 bpm of CLARIFY India cohort were higher than ROW. In addition, only 2.5% and 22.9% patients in the present cohort of CLARIFY India and the ROW, respectively, achieved goal HR 60 bpm. Similar results were revealed in BEAUTIFUL trial enrolling stable CAD patients; more than half of patients demonstrated a baseline resting HR !70 bpm, which was associated with significantly higher risk of myocardial infarction, coronary revascularization, and death, even with ß-blockers. 29 An important finding of the trial was that ivabradine added to optimal preventive therapy further reduced the risk of coronary events such as MI by À36% and revascularization by À30%. 29 Ivabradine is a pure HR-lowering agent having a selective action on the sinus node and is thus devoid of the usual side effects of b-blockers. In light of the above data, taking a step forward in the management of coronary patients, recent guidelines now recommend ivabradine for heart rate reduction as a second line treatment in the management of coronary patients.
11
Voluntary enrolment of patients by physicians contributed inherent selection bias. In particular, the CLARIFY India cohort included patients attending outpatient clinics/hospitals only in major city areas indicating urban bias. Despite these limitations, the registry has several strengths, including a large number of participating countries, making the results more generalizable.
Conclusion
The baseline results of the Indian cohort from CLARIFY registry indicate that there is a high prevalence and poor control of cardiovascular risk factors. Systematic approaches to improve control of modifiable risk factors and increase the long-term use of essential primary and secondary prevention medications are required to fulfil the lacuna in the management of stable CAD in current clinical practice.
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